根据美国证券交易委员会（SEC）最新披露的文件，Apimeds Pharmaceuticals US（APUS）已就其核心产品Apitox达成一项重要协议。该公司获得了该产品在韩国诊所领域的100%独家权利，同时在美国市场享有25%的特许权使用费，并可参与海外市场25%的收入分成。
这一战略性安排标志着APUS在商业化布局上的关键一步。协议条款清晰界定了各区域市场的利益分配机制——韩国市场侧重权利掌控，美国及海外市场则通过收益共享模式实现多方共赢。
文件内容显示，此次权利与收益分配方案已正式确立，为Apitox的全球市场推广奠定了明确的商业框架。相关财务条款的具体实施细节，市场将持续关注其在各区域的落地进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.